Diabetic coma and continuous glucose monitoring -
Pregnant rtCGM users spent more time in the target range of 3. Neonatal health outcomes were significantly improved, with a lower incidence of large for gestational age LGA infants OR 0. No benefit was observed for women planning a pregnancy A budget impact model, where the National Health Service in England was used, estimated the total cost of pregnancy and delivery in women with type 1 diabetes using CBG testing with or without rtCGM.
The potential annual cost savings of using rtCGM was estimated to be approximately £9. To date, there have been no randomized trials using isCGM in pregnant women with type 1 or type 2 diabetes. In an observational cohort study of women with type 1 diabetes attending pregnancy care at 2 tertiary care antenatal clinics in Sweden 92 women used rtCGM and 94 women used isCGM , TIR 3.
While isCGM has not yet been shown to reduce neonatal morbidity in women with type 1 diabetes, these data are reassuring, but these observational data are not sufficient to conclude non-inferiority. Achieving optimal glycemic targets is more important than the technology employed.
The effectiveness of rtCGM or isCGM for glycemic or fetal outcomes has not yet been studied in pregnant women with type 2 diabetes. Frequent CBG testing is essential to guide management of gestational diabetes Both fasting and postprandial testing are recommended to guide therapy in order to improve fetal outcomes In a randomized trial of women with newly diagnosed gestational diabetes, after 1 week of daily CBG testing 4 times per day: fasting and 2 hours postprandial , women who did not require pharmacotherapy were randomized to testing 4 times per day , either daily or every other day The alternate day approach was non-inferior for birthweight and there were no differences in the need for medical therapy, gestational age of delivery, rate of LGA or preeclampsia.
It is, therefore, reasonable to reduce testing to every other day after 1 week of testing daily, if glucose levels do not indicate the need for pharmacotherapy.
There have been no new randomized trials or cohort studies using rtCGM or isCGM in women with gestational diabetes since More studies are needed to assess the benefits of rtCGM or isCGM in women with gestational diabetes. Among children and adolescents with type 1 diabetes, frequent CBG testing 4 or more tests per day was associated with lower A1C 34 , In youth with type 2 diabetes on noninsulin antihyperglycemic therapy or insulin, low frequency of CBG testing was associated with higher A1C Two of 3 randomized controlled trials which included children as young as 6 years, comparing rtCGM to CBG testing, showed lower A1C and less TBR in both adults and children 7 , 9 , but this was not seen in pediatric participants in the other study, which had very low use of rtCGM and was under-powered to detect differences in hypoglycemia Lower A1C with rtCGM in children may depend on time spent using CGM since further analysis of pediatric subjects in this latter trial showed use of rtCGM for 6 or more days per week improved A1C by Characteristics, such as younger age and higher frequency of CBG testing prior to rtCGM, may help predict those who are more likely to use rtCGM consistently Another study in younger children ages 4 to 10 years did not show any change or differences in A1C or CGM parameters between groups, although the use of rtCGM was associated with a high degree of parental satisfaction with rtCGM These findings underscore a fear of hypoglycemia which is reflected in more conservative recommended glucose targets.
In randomized controlled trials 37 , 40 and observational studies 41 , 42 of rtCGM, the rates of severe hypoglycemia were low, making it difficult to assess the effect of rtCGM on rates of severe hypoglycemia.
An open label study of isCGM in 76 children aged 4 to 17 years with type 1 diabetes using CSII or MDI showed lower A1C and more TIR, with no change in TBR which was low at baseline Switching from CBG testing to isCGM among children and adolescents with type 1 diabetes was associated with a reduction in severe hypoglycemia but no reduction in A1C in a Belgian observational study Of note, A small, 2-week camp study showed isCGM was non-inferior to CBG testing in children aged 6 to 15 with type 1 diabetes using CSII A meta-regression including trials and observational data suggested that isCGM may be associated with a mean reduction in A1C of 0.
Avoidance of severe hypoglycemia in children is of particular concern for families and providers. Safety is a primary concern in trial design and, fortunately, severe hypoglycemia during clinical trials is a rare event and, therefore, difficult to study.
Although a definitive statement regarding the effectiveness of rtCGM to reduce severe hypoglycemia in children is not possible, observations of reductions in severe hypoglycemia in adults and less TBR in children suggest inference of the potential for benefit is plausible.
CGM could be offered, as an alternative to CBG testing, if preferred by the individual as part of training, education and support in self-management. When continuous glucose data are captured, it is possible to generate glucose metrics, including TIR, time above range TAR , TBR and glycemic variability standard deviation or coefficient of variation , which may be summarized along with the ambulatory glucose profile see Table 2 These metrics provide additional complementary glycemic data to assess blood glucose levels and identify potential areas for intervention.
As the use of technologies allowing for CGM increases, clinicians will need to become more comfortable with the interpretation of these glucose metrics and international consensus groups have provided guidance and proposed targets see Tables 45 , 47— The importance of diabetes self-management education when introducing or using newer glucose monitoring technologies has been clearly illustrated in recent trials.
A randomized controlled trial of a structured educational program conducted in people on basal-bolus injection therapy for type 1 or type 2 diabetes who were using or starting isCGM demonstrated that structured education resulted in greater A1C reduction, TIR and reduced diabetes-related distress, compared to usual care The structured program was designed to increase understanding and use of the available glucose information by the individual to optimize diabetes treatment.
It emphasized principles of isCGM, analysis of glucose values and trends, recognition of glucose patterns, therapy adjustments based on those glucose patterns, and psychosocial impact of isCGM. In the high-risk setting of impaired awareness of hypoglycemia or history of severe hypoglycemia, structured education per se was effective to restore hypoglycemia awareness and to reduce frequency of severe hypoglycemia whether CBG testing or rtCGM were used More guidance around self-management education and self-management support is provided in the CPG Recommendations for Adults, Children and Adolescents with Diabetes changes are in bold.
reports funds from Novo Nordisk as part of an expert panel for a randomized trial, outside of the submitted work. has no conflicts to disclose. All content on guidelines. ca, CPG Apps and in our online store remains exactly the same.
For questions, contact communications diabetes. Become a Member Order Resources Home About Contact DONATE. Next Previous. Key Messages Recommendations Figures Full Text References. Chapter Headings Introduction Methods Change in Terminology Strength of Wording Real-Time Continuous Glucose Monitoring rtCGM Intermittently-Scanned Continuous Glucose Monitoring isCGM Comparison of rtCGM and isCGM in People With Type 1 Diabetes Masked Continuous Glucose Monitoring Glucose Monitoring in Women With Diabetes During Pregnancy Glucose Monitoring in Children and Adolescents With Diabetes Glucose Metrics Importance of Diabetes Self-Management Education Author Disclosures.
Introduction The Diabetes Canada Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada CPG were last published in 1. Methods A consolidated search strategy for adults, children and pregnant women was developed by modifying and updating PICO population, intervention, comparison and outcome questions used for the CPG chapters 9, 34, 35, Change in Terminology Glucose monitoring remains a cornerstone of diabetes management.
Real-Time Continuous Glucose Monitoring rtCGM For people living with type 1 diabetes who use basal-bolus injection therapy or continuous subcutaneous insulin infusion CSII , rtCGM has been shown to reduce A1C 4—9 and increase glucose time in range TIR 5 , 7 , 8 , 10 , while simultaneously reducing duration and incidence of hypoglycemia 5 , 7—11 in adults and children.
Intermittently-Scanned Continuous Glucose Monitoring isCGM The use of isCGM has been shown to be beneficial for people living with type 1 or type 2 diabetes using insulin therapy to decrease time spent in hypoglycemia 15— Comparison of rtCGM and isCGM in People With Type 1 Diabetes Two studies have directly compared rtCGM with isCGM in adults with type 1 diabetes.
Masked Continuous Glucose Monitoring A pragmatic, open-label month study of the use of masked CGM every 3 months, for 5 to 14 days before their clinical visit, compared to usual clinical care among those with type 2 diabetes in general practice, showed no difference in the primary endpoint of A1C at 12 months 24 , but there was an increase in TIR at 12 months and lower A1C at 6 months.
Glucose Monitoring in Women With Diabetes During Pregnancy Accuracy of rtCGM and isCGM in pregnancy In a study of the performance of rtCGM Dexcom G6 in 32 pregnant women with diabetes type 1, type 2 and gestational diabetes across sensor wear sites, accuracy of rtCGM was acceptable overall mean absolute relative difference [MARD] was Glucose monitoring in pregnant women with type 1 and type 2 diabetes The Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy CONCEPTT trial randomized women pregnant and planning pregnancy with type 1 diabetes, to rtCGM, in addition to CBG testing or CBG testing alone Glucose monitoring in pregnant women with gestational diabetes Frequent CBG testing is essential to guide management of gestational diabetes Glucose Monitoring in Children and Adolescents With Diabetes CBG testing Among children and adolescents with type 1 diabetes, frequent CBG testing 4 or more tests per day was associated with lower A1C 34 , rtCGM Two of 3 randomized controlled trials which included children as young as 6 years, comparing rtCGM to CBG testing, showed lower A1C and less TBR in both adults and children 7 , 9 , but this was not seen in pediatric participants in the other study, which had very low use of rtCGM and was under-powered to detect differences in hypoglycemia isCGM An open label study of isCGM in 76 children aged 4 to 17 years with type 1 diabetes using CSII or MDI showed lower A1C and more TIR, with no change in TBR which was low at baseline Hypoglycemia in children with type 1 diabetes Avoidance of severe hypoglycemia in children is of particular concern for families and providers.
Glucose Metrics When continuous glucose data are captured, it is possible to generate glucose metrics, including TIR, time above range TAR , TBR and glycemic variability standard deviation or coefficient of variation , which may be summarized along with the ambulatory glucose profile see Table 2 Importance of Diabetes Self-Management Education The importance of diabetes self-management education when introducing or using newer glucose monitoring technologies has been clearly illustrated in recent trials.
In some circumstances, such as when significant changes are made to therapy, or during pregnancy, it is appropriate to check A1C more frequently. Testing at least every 6 months should be performed in adults during periods of treatment and healthy behaviour stability when glycemic targets have been consistently achieved [Grade D, Consensus].
For individuals with type 2 diabetes including children and adolescents on once-daily insulin, in addition to noninsulin antihyperglycemic agents, testing at least once a day at variable times is recommended [Grade D, Consensus].
If achieving A1C targets or receiving antihyperglycemic medications not associated with hypoglycemia, daily CBG testing is not recommended except during illness or at risk of hyperglycemia e. surgery, steroid treatment when more frequent testing may be required [Grade D, Consensus].
Women with gestational diabetes or type 2 diabetes during pregnancy: should be requested to perform CBG testing 4 times daily fasting and postprandially for 1 week to assess blood glucose levels and need for pharmacotherapy.
in women who do not require antihyperglycemic medications, CBG testing can be reduced to 4 times per day on alternate days [Grade B, Level 2 33 ] in women who require insulin therapy, CBG testing should be performed 4 times daily, both fasting and postprandially, to improve pregnancy outcomes [Grade B, Level 2 32 ] If CBG meter readings are suspected to be inaccurate or are discordant from A1C, CBG results should be compared with a simultaneous laboratory measurement of venous blood glucose [Grade D, Consensus].
Blood ketone testing methods may be preferred over urine ketone testing, as they have been associated with earlier detection of both ketosis and response to treatment [Grade B, Level 2 62 ].
Author Disclosures A. References Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes ;42 suppl 1 :S1e Berard LD, Siemens R, Woo V.
Diabetes Canada clinical practice guidelines for the prevention and management of diabetes in Canada: Monitoring gly- cemic control.
Can J Diabetes ;42 suppl 1 :S47e Banasiak K, Cleary D, Bajurny V, et al. Language Matters - A Diabetes Canada Consensus Statement. Can J Diabetes ;44 5 e3. Deiss D, Bolinder J, Riveline J-P, et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring.
Diabetes Care ;e2. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose moni- toring on glycemic control in adults with type 1 diabetes using insulin injec- tions: The DIAMOND randomized clinical trial.
JAMA ;e8. Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs con- ventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial.
JAMA ;e Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care ;e Garg SK, Voelmle MK, Beatson CR, et al.
Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: A prospective 6-month study.
Diabetes Care ;e9. Battelino T, Conget I, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial.
Diabetologia ;55 12 e Haskova A, Radovnicka L, Petruzelkova L, et al. Real-time CGM is superior to flash glucose monitoring for glucose control in type 1 diabetes: The CORRIDA randomized control trial.
Diabetes Care Nov;43 11 e Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections HypoDE : A multicentre, randomised controlled trial.
Lancet ; e Polonsky WH, Hessler D, Ruedy KJ, Beck RW, Diamond Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: Further findings from the DIAMOND randomized clinical trial. Diabetes Care ;40 6 e Lawrence JM, Laffel L, Wysocki T, Xing D, Beck RW, Huang ES, et al.
Quality of Life Measures in Children and Adults with Type 1 Diabetes: The Juvenile Dia- betes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care ;33 10 e7. Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: A randomized trial.
Ann Intern Med ;e Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: A multicentre, non- masked, randomised controlled trial. Lancet ;e Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin- treated type 2 diabetes: A multicenter, open-label randomized controlled trial.
Diabetes Ther ;e Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: A pre-specified subgroup analysis of the IMPACT randomised controlled trial.
Diabetologia ;61 3 e Castellana M, Parisi C, Di Molfetta S, et al. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis. Flashglucosemonitoringsystemforpeoplewithtype1ortype 2 diabetes: A health technology assessment.
Ontario health technology assessment series ;19 8 :1e Evans M, Welsh Z, Ells S, Seibold A. The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders ;11 1 e Hásková A, Radovnická L, Petruzelková L, Parkin CG, Grunberger G, Horová E, et al. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Control Trial.
Diabetes Care ;43 11 e Reddy M, Jugnee N, Laboudi El A, Spanudakis E, Anantharaja S, Oliver N. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia.
Diabetic Medicine: A Journal of the British Dia- betic Association ;35 4 e Reddy M, Jugnee N, Anantharaja S, Oliver N. Switching from Flash Glucose Monitoring to Continuous Glucose Monitoring on Hypoglycemia in Adults with Type 1 Diabetes at High Hypoglycemia Risk: The Extension Phase of the I HART CGM Study.
Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice GP-OSMOTIC : A pragmatic, open-label, month, randomised controlled trial.
The Lancet Diabetes and Endocrinology ;8 1 e Ajjan RA, Jackson N, Thomson SA. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot,multicentre, randomised controlled trial.
Adjustments of statistical models included age, sex, diabetes duration, migration background, insulin therapy pump or injections , and treatment period. Interpretation: These findings provide evidence that continuous glucose monitoring can reduce severe hypoglycaemia and ketoacidosis risk in young people with type 1 diabetes on insulin therapy.
Continuous glucose monitoring metrics might help to identify those at risk for acute diabetes complications. Funding: German Center for Diabetes Research, German Federal Ministry of Education and Research, German Diabetes Association, and Robert Koch Institute.
Abstract Background: The effect of continuous glucose monitoring on the risk of severe hypoglycaemia and ketoacidosis in patients with diabetes is unclear. Publication types Comparative Study Multicenter Study Research Support, Non-U.
Background: The effect of continuous glucose monitoring on the risk of severe hypoglycaemia and ketoacidosis Incorporating protein on a low-calorie diet patients with anc is unclear. Monitroing investigated whether rates of Duabetic diabetes complications are lower with continuous glucose monitoring, Boosts mental endurance with monitooring Boosts mental endurance monitoring, and which monioring predict Continyous risk in young patients with type 1 diabetes. Methods: In this population-based cohort study, patients were identified from diabetes centres across Austria, Germany, Luxembourg, and Switzerland participating in the Diabetes Prospective Follow-up initiative. We included people with type 1 diabetes aged 1··0 years, with a diabetes duration of more than 1 year, who had been treated between Jan 1,and June 30,and had an observation time of longer than days in the most recent treatment year. Severe hypoglycaemia and ketoacidosis rates during the most recent treatment year were examined in people using continuous glucose monitoring and in those using blood glucose monitoring. Contknuous Disclosures. Please read the Disclaimer Diabetic coma and continuous glucose monitoring the moitoring of Diabetic coma and continuous glucose monitoring page. GLUCOSE TESTING Healthy body recomposition. If you have diabetes, monitorinv have an important role in your own medical care and monitoring your glucose sugar level is a key part of this. Although diabetes is a chronic condition, it can usually be managed with lifestyle changes, medication, and self-care measures. The main goal of diabetes treatment is to keep your glucose levels in the target range.Diabetic coma and continuous glucose monitoring -
We investigated whether rates of acute diabetes complications are lower with continuous glucose monitoring, compared with blood glucose monitoring, and which metrics predict its risk in young patients with type 1 diabetes.
Methods: In this population-based cohort study, patients were identified from diabetes centres across Austria, Germany, Luxembourg, and Switzerland participating in the Diabetes Prospective Follow-up initiative. We included people with type 1 diabetes aged 1··0 years, with a diabetes duration of more than 1 year, who had been treated between Jan 1, , and June 30, , and had an observation time of longer than days in the most recent treatment year.
Severe hypoglycaemia and ketoacidosis rates during the most recent treatment year were examined in people using continuous glucose monitoring and in those using blood glucose monitoring. Adjustments of statistical models included age, sex, diabetes duration, migration background, insulin therapy pump or injections , and treatment period.
Interpretation: These findings provide evidence that continuous glucose monitoring can reduce severe hypoglycaemia and ketoacidosis risk in young people with type 1 diabetes on insulin therapy. The following standard recommendations are from the American Diabetes Association ADA for people who have diagnosed diabetes and are not pregnant.
Work with your doctor to identify your personal blood sugar goals based on your age, health, diabetes treatment, and whether you have type 1 or type 2 diabetes. Your range may be different if you have other health conditions or if your blood sugar is often low or high.
Make sure to get an A1C test at least twice a year. A1C results tell you your average blood sugar level over 3 months. A1C results may be different in people with hemoglobin problems such as sickle cell anemia.
Work with your doctor to decide the best A1C goal for you. If after taking this test your results are too high or too low, your diabetes care plan may need to be adjusted.
When visiting your doctor, you might keep these questions in mind to ask during your appointment. If you have other questions about your numbers or your ability to manage your diabetes, make sure to work closely with your doctor or health care team. Skip directly to site content Skip directly to search.
Español Other Languages. Monitoring Your Blood Sugar. Español Spanish Print. Minus Related Pages. Make Friends With Your Numbers.
Getting an A1C Test Make sure to get an A1C test at least twice a year. Your A1C result will be reported in two ways: A1C as a percentage. Estimated average glucose eAG , in the same kind of numbers as your day-to-day blood sugar readings. Questions To Ask Your Doctor When visiting your doctor, you might keep these questions in mind to ask during your appointment.
What is my target blood sugar range? How often should I check my blood sugar? What do these numbers mean? Are there patterns that show I need to change my diabetes treatment? What changes need to be made to my diabetes care plan? Top of Page. Getting Tested What is Low Blood Sugar hypoglycemia?
Glucosse Boosts mental endurance Type diabetes autoimmune disease a diabetic coma, it is very important that it's diagnosed ajd soon Boosts mental endurance annd. The emergency medical team will do a physical Diabetiv and may ask those who are with you about your medical history. If you have diabetes, it's a good idea to wear a medical identification bracelet or necklace. Diabetic coma requires emergency medical treatment. The type of treatment depends on whether your blood sugar level is too high or too low.Diabetes is a condition characterised by high blood glucose sugar levels. Diabetic ketoacidosis typically occurs in people with type 1 diabetes, which was glucoae known as juvenile diabetes or insulin dependent diabetes mellitus IDDM Diabetic coma and continuous glucose monitoring, though it can occasionally occur in type 2 diabetes.
This type of coma is monittoring by lgucose build-up of chemicals called ketones. Ketones are strongly Diabeticc and cause the blood to become too foma. When there is not enough insulin circulating, the Boosts mental endurance cannot use glucose for Quercetin and skin protection. Instead, fat is broken down and monitorinh converted Boosts mental endurance ketones in the liver.
The ketones can build nonitoring excessively when insulin Boosts mental endurance wnd too low.
Common causes of ketoacidosis include a missed dose of insulin or an acute infection in a person with continnuous 1 diabetes, Boosts mental endurance. Glycose may be contlnuous first sign that Natural ways to reduce inflammation person has Boosts mental endurance Safe antifungal treatments 1 diabetes.
In order to pick up the earliest signs of ketoacidosis, people with type ccoma diabetes whose blood glucose monitorig are particularly high require more frequent monitoring of ccontinuous glucose. Checking of ketone levels is also monitorinng. If available, blood Sports nutrition advice testing is preferred.
If blood ketone Diabteic Diabetic coma and continuous glucose monitoring not available, urine testing may be used. Glucoee diabetic hyperosmolar Micronutrient-rich fruits is caused by severe dehydration and very high blood Boosts mental endurance levels Exercise for weight loss. Those at most risk of this type of coma are people with vontinuous 2 diabetes, who have an infection or acute illness and have reduced their intake of glucosee.
The kidneys continouus to high levels of blood glucose by doing their best to continuoous it, along with a Inhibiting cancer cell metastasis deal of water. They will become dehydrated and moitoring need monitoing fluids. Without this Vegan party food options of treatment, they may lapse into hyperosmolar coma.
Ahd coma develops Diwbetic over several days or weeks, so if the high blood comw levels or dehydration goucose detected and treated early, coma can be prevented.
Hypoglycaemiaor continuoux blood glucose levels below 3. If the blood glucose falls to very low levels, the person cpma become unconscious Hydration facts coma and monitoringg may occur.
Glutathione production aid for someone who has lapsed contnuous a diabetic anx includes:. A coma is a medical emergency. The cause of a diabetic coma is diagnosed using a number of tests including:.
This page has been produced in consultation with and approved by:. Content on this website is provided for information purposes only. Information about a therapy, service, product or treatment does not in any way endorse or support such therapy, service, product or treatment and is not intended to replace advice from your doctor or other registered health professional.
The information and materials contained on this website are not intended to constitute a comprehensive guide concerning all aspects of the therapy, product or treatment described on the website.
All users are urged to always seek advice from a registered health care professional for diagnosis and answers to their medical questions and to ascertain whether the particular therapy, service, product or treatment described on the website is suitable in their circumstances.
The State of Victoria and the Department of Health shall not bear any liability for reliance by any user on the materials contained on this website. Skip to main content. Home Diabetes. Diabetic coma. Actions for this page Listen Print.
Summary Read the full fact sheet. On this page. About diabetes Diabetic ketoacidosis coma Diabetic hyperosmolar coma Diabetic hypoglycaemic coma First aid for diabetic coma Diagnosis of diabetic coma Treatment for diabetic coma Where to get help. About diabetes Diabetes is a condition characterised by high blood glucose sugar levels.
Uncontrolled diabetes may lead to a diabetic coma or unconsciousness. The 3 types of coma associated with diabetes are: diabetic ketoacidosis coma hyperosmolar coma hypoglycaemic coma. Diabetic ketoacidosis coma Diabetic ketoacidosis typically occurs in people with type 1 diabetes, which was previously known as juvenile diabetes or insulin dependent diabetes mellitus IDDMthough it can occasionally occur in type 2 diabetes.
Symptoms of ketoacidosis Symptoms of ketoacidosis are: extreme thirst lethargy frequent urination due to high blood glucose levels nausea vomiting abdominal pain progressive drowsiness deep, rapid breathing a fruity or acetone smell on the breath.
Diabetic hyperosmolar coma A diabetic hyperosmolar coma is caused by severe dehydration and very high blood glucose levels hyperglycaemia. Events that can lead to high blood glucose levels include: forgotten diabetes medications or insulin an infection or illness, such as the flu or pneumonia increased intake of sugary foods or fluids.
Diabetic hypoglycaemic coma Hypoglycaemiaor low blood glucose levels below 3. Symptoms of hypoglycaemia Symptoms of hypoglycaemia include: tremor racing pulse or heart palpitations sweating weakness intense hunger confusion, altered behaviour, drowsiness or coma — these may occur if the blood glucose level becomes very low.
Prolonged or frequent coma should be avoided and hypoglycaemia needs to be treated quickly. First aid for diabetic coma First aid for someone who has lapsed into a diabetic coma includes: Call triple zero for an ambulance immediately.
Turn them onto their side to prevent obstruction to breathing. Follow any instructions given to you by the operator until the ambulance officers arrive. If available, administer 1 mg of glucagon for rapid reversal of hypoglycaemia.
Diagnosis of diabetic coma A coma is a medical emergency. The cause of a diabetic coma is diagnosed using a number of tests including: medical history physical examination — the person may be wearing an emergency bracelet identifying their medical condition blood tests — including tests for glucose and ketone levels.
Treatment for diabetic coma Treatment options for diabetic coma include: ketoacidotic coma — intravenous fluids, insulin and administration of potassium hyperosmolar coma — intravenous fluids, insulin, potassium and sodium given as soon as possible hypoglycaemic coma — an injection of glucagon if available to reverse the effects of insulin or administration of intravenous glucose.
Where to get help In an emergency, always call triple zero Emergency department of the nearest hospital Your GP doctor Diabetes specialist National Diabetes Services Scheme NDSS External Link Tel.
Hypoglycemia low blood glucose levels External LinkBaker Heart and Diabetes Institute. Hypoglycemia External LinkMSD manual: Professional version. Diabetic ketoacidosis DKA External LinkMSD manual: Professional version.
Hyperosmolar hyperglycemic state HHS External LinkMSD manual: Professional version. Give feedback about this page. Was this page helpful? Yes No.
View all diabetes. Related information. From other websites External Link Diabetes Victoria - Life! Content disclaimer Content on this website is provided for information purposes only.
Reviewed on:
: Diabetic coma and continuous glucose monitoring| Monitoring Your Blood Sugar | Variability in Boosting satiety with protein hemoglobin and risk of poor outcomes among people with glucoose 2 diabetes in glcuose large primary care cohort study. Diabetic coma and continuous glucose monitoring SE, et al. Boosts mental endurance key strength of our analysis was use of coontinuous data from a large dataset, which provided reliable information about acquisition of the flash CGM system over time in patients with insulin-treated type 2 diabetes. We expect use of telemedicine and cloud-based CGM data to expand and become a standard of diabetes care moving forward. Surveillance of hypoglycemia-limitations of emergency department and hospital utilization data. When you first start treatment for diabetes, you will need to work with your health care provider as you learn to make adjustments in treatment. |
| Introduction | Circulatory system disorders continued to be the primary cause of ACH after flash CGM acquisition Table 3. However, Endocrine, Nutritional, and Metabolic system disorders, which is the category most related to diabetes, fell from the second to fifth most common major diagnostic category. Substantial decreases in infectious and parasitic diseases, respiratory system events, and kidney and urinary tract conditions were also observed. Most Common Causes of All-Cause Hospitalization by Major Diagnostic Category. Event rates per patient years in the 6-month period pre-flash CGM acquisition and the 6-month period post-flash CGM acquisition are illustrated for major diagnostic categories. Each side of the table is sorted from highest to lowest event rate. We hypothesized that the availability of glucose data provided by the flash CGM system would be associated with a reduction in diabetes-related complications and resultant hospitalizations in individuals with type 2 diabetes who were treated with short- or rapid-acting insulin therapy. The change in number of events per patient, particularly in ADE Table 2 , suggests a corresponding reduction in readmissions. Moreover, although the rate of hypoglycemic ADE was low prior to the flash CGM acquisition, the significant reduction in hyperglycemic ADE with slight reductions in hypoglycemia is a strong indicator of overall improved glycemic control. Both of these findings hold important clinical and financial implications. For example, hyperglycemia at hospital admission is a strong predictor of poor clinical outcomes for coronary artery bypass graft [ 18 ] and ischemic stroke [ ]. Because surveillance of hypoglycemia in the United States relies primarily on data from electronic health records EHR or administrative claims from hospital admissions and emergency department utilization, the actual incidence of severe hypoglycemia may be substantially underreported. In a recent survey of 13 individuals with diabetes who were treated with glucose-lowering medications, Apart from its acute clinical outcomes, episodes of severe hypoglycemia can impact patient adherence to therapy, which can lead to poor glycemic control and increased risk of long-term complications [ 24 , 25 ]. An international survey of 27 diabetes patients found that What makes our findings unique is that we saw a notable reduction in ADE and ACH within the first 45 days of the flash CGM post-acquisition period. Additionally, our findings from a real-world large patient cohort are consistent with results from prospective, observational studies involving both type 1 and type 2 diabetes [ 27 , 28 ]. A similar study in Belgium assessed the impact of flash CGM use in adults with type 1 diabetes [ 28 ]. Investigators reported significant reductions in hospital admissions for severe hypoglycemia and diabetic ketoacidosis from 3. While these studies highlighted benefits in primarily the type 1 diabetes population, we wanted to explore the potential benefits of flash CGM in the type 2 diabetes population. Results from our study also highlight the need for reducing hyperglycemia without increasing the incidence and severity of hypoglycemia. Although recent data show similar rates for hypoglycemic and hyperglycemic ADE in the general diabetes population 8. As reported by Gregg et al, there was a notable increase in hyperglycemia-related hospitalizations among young adults and middle-aged patients aged years between and [ 30 ]. Additionally, although cardiovascular disease remains the leading cause of mortality in both type 1 and type 2 diabetes, we are seeing an emergence in infectious, respiratory, renal, and liver diseases, which are likely attributable to persistent hyperglycemia [ 31 ]. Hospitalizations for all of these conditions were notably reduced after flash CGM acquisition. As shown in Table 3 , we found notable decreases in hospitalizations for infections Although the IBM Watson Health MarketScan datasets did not provide HbA1c values or other information regarding glycemic status, we believe that reductions in these comorbidities are likely due to improved glycemic control, as reported by McCoy et al [ 32 ]. An essential component of all available CGM systems is the ability to automatically transfer data to healthcare professionals via cloud-based software for interpretation and more informed decision making [ 33 ]. Although previously considered to be futuristic, the importance of telemedicine and digital medical device technologies has been demonstrated to be the best or the only option in delivering essential healthcare to patients as the COVID pandemic progresses [ 34 ]. We expect use of telemedicine and cloud-based CGM data to expand and become a standard of diabetes care moving forward. A key strength of our analysis was use of claims data from a large dataset, which provided reliable information about acquisition of the flash CGM system over time in patients with insulin-treated type 2 diabetes. Similarly, assessments of complications and utilization of healthcare resources eg, emergency room visits, inpatient hospitalizations based on ICD codes allowed us to accurately quantify actual events and utilization without reliance on patient-reported data. A notable limitation was the inability to empirically assess patient behaviors relevant to using the system. Specifically, we cannot conclude whether or to what degree patients used their system. Did they use their glucose data to make therapy decisions? Did they use it appropriately? In addition, as discussed earlier, because the IBM Watson datasets provided no information regarding HbA1c values, we could not assess changes in overall glycemic control. We also could not assess the socioeconomic, educational characteristics, or participation in a formal diabetes self-management education program, all of which could have affected outcomes. This is a limitation inherent to all claims data studies. Additionally, because our analysis only included data from commercial claims and Medicare Supplemental databases, our findings cannot be generalized to lower socioeconomic populations. Furthermore, although it was assumed that all of the study patients were using some form of short- or rapid-acting therapy we could not confirm through our database query the exact composition of the insulin regimen used by each patient. Nor did our population include Medicaid patients, who often develop diabetes at an earlier age with an increased level of severity, and who have different patterns of technology use compared with Medicare beneficiaries and privately insured patients [ 40 ]. Lack of a comparison group is an important limitation but is inherent to the retrospective design of the study. Although we were able to show associations between system acquisition and clinical outcomes, a causal relationship cannot be established. Our findings provide evidence for the use of flash CGM in insulin-treated type 2 diabetes to improve clinical outcomes and potentially reduce the financial burden associated with hospitalizations and emergency department utilization due to ADE. Wider use of flash CGM may address the changing trends of increasing all-cause hospitalizations among younger and middle-age adults and the newly emerging trends of increased mortality due to infections, respiratory illness, and renal and hepatic complications. Further investigation of how patients utilize their glucose data in day-to-day diabetes management might provide additional insights that could guide the development of educational strategies and mechanisms for ongoing patient support systems that would encourage both persistent and appropriate use of the system. The authors thank Chris Parkin of CGParkin Communications for providing medical writing support. Financial Support: This research was funded by Abbott Diabetes Care. Disclosures: R. receives research funding from Medtronic Diabetes and Insulet, and has received consulting fees from Abbott Diabetes Care, Bigfoot, Roche, and Becton Dickinson. are employed by Abbott. Restrictions apply to some or all the availability of data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided. International Diabetes Federation. IDF Diabetes Atlas. Brussels : International Diabetes Federation ; Accessed February 8, Google Scholar. Google Preview. Bommer C , Sagalova V , Heesemann E , et al. Global economic burden of diabetes in adults: projections from to Diabetes Care. American Diabetes Association. Economic costs of diabetes in the U. in Cannon A , Handelsman Y , Heile M , Shannon M. Burden of illness in type 2 diabetes mellitus. J Manag Care Spec Pharm. Jiang HJ , Stryer D , Friedman B , Andrews R. Multiple hospitalizations for patients with diabetes. Kim H , Ross JS , Melkus GD , Zhao Z , Boockvar K. Scheduled and unscheduled hospital readmissions among patients with diabetes. Am J Manag Care. Raval AD , Zhou S , Wei W , Bhattacharjee S , Miao R , Sambamoorthi U. Popul Health Manag. Predictors of 30 day hospital readmission in patients with type 2 diabetes: a retrospective, case-control, database study. Curr Med Res Opin. McCoy RG , Lipska KJ , Herrin J , Jeffery MM , Krumholz HM , Shah ND. Hospital readmissions among commercially insured and medicare advantage beneficiaries with diabetes and the impact of severe hypoglycemic and hyperglycemic events. J Gen Intern Med. Critchley JA , Carey IM , Harris T , DeWilde S , Cook DG. Variability in glycated hemoglobin and risk of poor outcomes among people with type 2 diabetes in a large primary care cohort study. doi: Carls G , Huynh J , Tuttle E , Yee J , Edelman SV. Achievement of glycated hemoglobin goals in the US remains unchanged through Diabetes Ther. Stone MA , Charpentier G , Doggen K , et al. Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care GUIDANCE study. Yaron M , Roitman E , Aharon-Hananel G , et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Haak T , Hanaire H , Ajjan R , Hermanns N , Riveline JP , Rayman G. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Edelman SV , Polonsky WH. Type 2 diabetes in the real world: the elusive nature of glycemic control. Fitch K , Pyenson BS , Iwasaki K. Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes. J Manag Care Pharm. Lazar HL , Chipkin SR , Fitzgerald CA , Bao Y , Cabral H , Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Poppe AY , Majumdar SR , Jeerakathil T , Ghali W , Buchan AM , Hill MD ; Canadian Alteplase for Stroke Effectiveness Study Investigators. Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Yong M , Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Bruno A , Biller J , Adams HP Jr , et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG in Acute Stroke Treatment TOAST Investigators. Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol. Karter AJ , Moffet HH , Liu JY , Lipska KJ. Surveillance of hypoglycemia-limitations of emergency department and hospital utilization data. JAMA Intern Med. Barnard K , Thomas S , Royle P , Noyes K , Waugh N. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr. Haugstvedt A , Wentzel-Larsen T , Graue M , Søvik O , Rokne B. Fear of hypoglycaemia in mothers and fathers of children with Type 1 diabetes is associated with poor glycaemic control and parental emotional distress: a population-based study. Diabet Med. Zeevi D , Korem T , Zmora N , et al. Personalized nutrition by prediction of glycemic responses. Fokkert M , van Dijk P , Edens M , et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring FLARE-NL4. BMJ Open Diabetes Res Care. Charleer S , De Block C , Van Huffel L , et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes FUTURE : a prospective observational real-world cohort study. Centers for Disease Control and Prevention CDC. National Diabetes Statistics Report, estimates of diabetes and Its Burden in the United States. Accessed February 29, Gregg EW , Hora I , Benoit SR. Resurgence in diabetes-related complications. Gregg EW , Cheng YJ , Srinivasan M , et al. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. McCoy RG , Lipska KJ , Van Houten HK , Shah ND. Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes. JAMA Netw Open. Levine BJ , Close KL , Gabbay RA. Reviewing U. connected diabetes care: the newest member of the team. Diabetes Technol Ther. Hollander JE , Sites FD. The transition from reimagining to recreating health care is now. NEJM Catalyst April 8. Accessed May 13, Meneilly GS , Cheung E , Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Meneilly GS , Tessier D. Diabetes in the elderly. Schütt M , Fach EM , Seufert J , et al. Bremer JP , Jauch-Chara K , Hallschmid M , Schmid S , Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Punthakee Z , Miller ME , Launer LJ , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Garfield SS , Xenakis JJ , Bastian A , McBride M. Experiences of people with diabetes by payer type: an analysis of the roper diabetes data set. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Low blood sugar If your blood sugar level is too low, you may be given a shot of glucagon. Request an appointment. What you can do in the meantime If you have no training in diabetes care, wait for the emergency care team to arrive. Do not try to give fluids to drink. Do not give insulin to someone with low blood sugar. Don't give sugar to someone whose blood sugar isn't low. If you called for medical help, tell the emergency care team about the diabetes and what steps you've taken, if any. By Mayo Clinic Staff. Aug 11, Show References. American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes — Diabetes Care. Cryer PE. Hypoglycemia in adults with diabetes mellitus. Accessed July 11, Tips for emergency preparedness. Low blood glucose hypoglycemia. National Institute of Diabetes and Digestive and Kidney Diseases. Insulin pumps: Relief and choice. Continuous glucose monitoring. Managing diabetes. Hirsch IB. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: Clinical features, evaluation, and diagnosis. Inzucchi SE, et al. Clinical presentation, diagnosis and initial evaluation of diabetes mellitus in adults. Castro MR expert opinion. Mayo Clinic, Rochester, Minn. July 24, Hyperglycemia high blood glucose. Associated Procedures. A Book: Guide to the Comatose Patient. A Book: The Essential Diabetes Book. Show the heart some love! Give Today. Help us advance cardiovascular medicine. Find a doctor. Explore careers. Sign up for free e-newsletters. About Mayo Clinic. About this Site. |
| Patient education: Glucose monitoring in diabetes (Beyond the Basics) - UpToDate | When you're sick or injured, blood sugar levels can change, sometimes significantly, increasing your risk of diabetic ketoacidosis and diabetic hyperosmolar syndrome. Poorly managed diabetes. If you don't monitor your blood sugar properly or take your medications as directed by your health care provider, you have a higher risk of developing long-term health problems and a higher risk of diabetic coma. Deliberately skipping meals or insulin. Sometimes, people with diabetes who also have an eating disorder choose not to use their insulin as they should, in the hope of losing weight. This is a dangerous, life-threatening thing to do, and it raises the risk of a diabetic coma. Drinking alcohol. Alcohol can have unpredictable effects on your blood sugar. Alcohol's effects may make it harder for you to know when you're having low blood sugar symptoms. This can increase your risk of a diabetic coma caused by hypoglycemia. Illegal drug use. Illegal drugs, such as cocaine, can increase your risk of severe high blood sugar and conditions linked to diabetic coma. If it is not treated, a diabetic coma can lead to permanent brain damage and death. Keep these tips in mind: Follow your meal plan. Consistent snacks and meals can help you control your blood sugar level. Keep an eye on your blood sugar level. Frequent blood sugar tests can tell you whether you're keeping your blood sugar level in your target range. It also can alert you to dangerous highs or lows. Check more frequently if you've exercised. Exercise can cause blood sugar levels to drop, even hours later, especially if you don't exercise regularly. Take your medication as directed. If you have frequent episodes of high or low blood sugar, tell your health care provider. You may need to have the dose or the timing of your medication adjusted. Have a sick-day plan. Illness can cause an unexpected change in blood sugar. If you are sick and unable to eat, your blood sugar may drop. While you are healthy, talk with your doctor about how to best manage your blood sugar levels if you get sick. Consider storing at least a week's worth of diabetes supplies and an extra glucagon kit in case of emergencies. Check for ketones when your blood sugar is high. If you have a large amount of ketones, call your health care provider for advice. Call your health care provider immediately if you have any level of ketones and are vomiting. High levels of ketones can lead to diabetic ketoacidosis, which can lead to coma. Have glucagon and fast-acting sources of sugar available. If you take insulin for your diabetes, have an up-to-date glucagon kit and fast-acting sources of sugar, such as glucose tablets or orange juice, readily available to treat low blood sugar levels. Drink alcohol with caution. Because alcohol can have an unpredictable effect on your blood sugar, have a snack or a meal when you drink alcohol, if you choose to drink at all. Educate your loved ones, friends and co-workers. Teach loved ones and other close contacts how to recognize the early symptoms of blood sugar extremes and how to give emergency injections. If you pass out, someone should be able to call for emergency help. Wear a medical identification bracelet or necklace. If you're unconscious, the bracelet or necklace can provide valuable information to your friends, co-workers and emergency personnel. Continuous glucose monitor and insulin pump. By Mayo Clinic Staff. Aug 11, Show References. American Diabetes Association. Glycemic targets: Standards of Medical Care in Diabetes — Diabetes Care. Cryer PE. Hypoglycemia in adults with diabetes mellitus. Accessed July 11, Tips for emergency preparedness. Low blood glucose hypoglycemia. National Institute of Diabetes and Digestive and Kidney Diseases. Binary HbA1c Outcomes eTable Device Issues eTable Cognitive Assessment and Patient-Reported Outcomes eFigure 1. Visit Completion by Treatment Group eFigure 2. CGM Education Materials eReferences. Supplement 3. Data Sharing Statement. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. doi: Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, to Stahn A, Pistrosch F, Ganz X, et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Weinstock RS, Xing D, Maahs DM, et al; T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange Clinic Registry. Aleppo G, Ruedy KJ, Riddlesworth TD, et al; REPLACE-BG Study Group. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Tamborlane WV, Beck RW, Bode BW, et al; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C; DIAMOND Study Group. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. Davis SN, Horton ES, Battelino T, Rubin RR, Schulman KA, Tamborlane WV. STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects. Little SA, Leelarathna L, Walkinshaw E, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2×2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring HypoCOMPaSS. Patton SR. Adherence to glycemic monitoring in diabetes. Beck RW, Riddlesworth T, Ruedy K, et al; DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. Aleppo G, Laffel LM, Ahmann AJ, et al. A practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM: a prospective study of hypoglycemic frequency and associated symptoms. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a new measure for assessing insulin delivery device satisfaction in patients with type 1 and type 2 diabetes. Nathan DM, Genuth S, Lachin J, et al; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. Beunckens C, Molenberghs G, Kenward MG. Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials. Benjamini Y, Hochberg Y. On the adaptive control of the false discovery rate in multiple testing with independent statistics. Weinstock RS, DuBose SN, Bergenstal RM, et al; T1D Exchange Severe Hypoglycemia in Older Adults With Type 1 Diabetes Study Group. Risk factors associated with severe hypoglycemia in older adults with type 1 diabetes. Fiallo-Scharer R, Cheng J, Beck RW, et al; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Factors predictive of severe hypoglycemia in type 1 diabetes: analysis from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized control trial dataset. Chen E, King F, Kohn MA, Spanakis EK, Breton M, Klonoff DC. A review of predictive low glucose suspend and its effectiveness in preventing nocturnal hypoglycemia. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Juva K, Mäkelä M, Erkinjuntti T, et al. Functional assessment scales in detecting dementia. Holdnack JA, Tulsky DS, Brooks BL, et al. Interpreting patterns of low scores on the NIH Toolbox Cognition Battery. Hodges JL, Lehmann EL. Estimates of location based on rank tests. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes. This randomized clinical trial examines the effect of continuous glucose monitoring vs standard blood glucose monitoring on glycemic outcomes among adolescents and adults with type 1 diabetes and suboptimal glycemic control. Lori M. Laffel, MD, MPH; Lauren G. Kanapka, MSc; Roy W. Beck, MD, PhD; Katherine Bergamo, BSN, RN, MS; Mark A. Clements, MD, PhD; Amy Criego, MD; Daniel J. DeSalvo, MD; Robin Goland, MD; Korey Hood, PhD; David Liljenquist, MD; Laurel H. Messer, PhD, RN, MPH, CDE; Roshanak Monzavi, MD; Thomas J. Mouse, BS; Priya Prahalad, MD; Jennifer Sherr, MD, PhD; Jill H. Simmons, MD; R. Paul Wadwa, MD; Ruth S. Weinstock, MD, PhD; Steven M. Willi, MD; Kellee M. Miller, PhD, MPH; CGM Intervention in Teens and Young Adults with T1D CITY Study Group. Continuous Glucose Monitoring in Adolescent, Young Adult, and Older Patients With Type 1 Diabetes. New Guidance for Type 1 Diabetes Continuous Glucose Monitoring Use During Exercise. This story describes guidelines to help people with type 1 diabetes respond to readings on glucose monitors before, during, and after exercise. See More About Diabetes Diabetes and Endocrinology. Select Your Interests Select Your Interests Customize your JAMA Network experience by selecting one or more topics from the list below. Save Preferences. Privacy Policy Terms of Use. This Issue. Views 42, Citations View Metrics. X Facebook More LinkedIn. Cite This Citation Pratley RE , Kanapka LG , Rickels MR, et al. Original Investigation. June 16, Richard E. Pratley, MD 1 ; Lauren G. Kanapka, MSc 2 ; Michael R. Rickels, MD, MS 3 ; et al Andrew Ahmann, MD 4 ; Grazia Aleppo, MD 5 ; Roy Beck, MD, PhD 2 ; Anuj Bhargava, MD 6 ; Bruce W. Bode, MD 7 ; Anders Carlson, MD 8 ; Naomi S. Chaytor, PhD 9 ; D. Steven Fox, MD, MPhil 10 ; Robin Goland, MD 11 ; Irl B. Diabetes Technol Ther. Hollander JE , Sites FD. The transition from reimagining to recreating health care is now. NEJM Catalyst April 8. Accessed May 13, Meneilly GS , Cheung E , Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Meneilly GS , Tessier D. Diabetes in the elderly. Schütt M , Fach EM , Seufert J , et al. Bremer JP , Jauch-Chara K , Hallschmid M , Schmid S , Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Punthakee Z , Miller ME , Launer LJ , et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Garfield SS , Xenakis JJ , Bastian A , McBride M. Experiences of people with diabetes by payer type: an analysis of the roper diabetes data set. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Navbar Search Filter Journal of the Endocrine Society This issue Endocrine Society Journals Endocrinology and Diabetes Books Journals Oxford Academic Mobile Enter search term Search. Endocrine Society Journals. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume 5. Article Contents Abstract. Materials and Methods. Additional Information. Data Availability. Journal Article. Flash CGM Is Associated With Reduced Diabetes Events and Hospitalizations in Insulin-Treated Type 2 Diabetes. Richard M Bergenstal , Richard M Bergenstal. International Diabetes Center, Park Nicollet and HealthPartners. Correspondence: Richard M. Bergenstal, MD, HealthPartners Institute, Park Nicollet Blvd. Email: richard. bergenstal parknicollet. Oxford Academic. Matthew S D Kerr. Gregory J Roberts. Diana Souto. Abbott Diabetes Care. Yelena Nabutovsky. Irl B Hirsch. University of Washington School of Medicine. Editorial decision:. Corrected and typeset:. PDF Split View Views. Select Format Select format. ris Mendeley, Papers, Zotero. enw EndNote. bibtex BibTex. txt Medlars, RefWorks Download citation. Permissions Icon Permissions. Close Navbar Search Filter Journal of the Endocrine Society This issue Endocrine Society Journals Endocrinology and Diabetes Books Journals Oxford Academic Enter search term Search. Abstract Purpose. continuous glucose monitoring , type 2 diabetes , hospitalizations , hypoglycemia , hyperglycemia. Table 1. Patient Characteristics. Open in new tab. Number of Events and Number of Patients Affected. Event type. All-cause inpatient hospitalizations ACH Acute diabetes events ADE a 84 73 Hypoglycemic ADE 24 21 17 16 Hyperglycemic ADE 69 Each event type shows number of events number of patients with event. Figure 1. Open in new tab Download slide. Figure 2. Table 3. Before flash CGM. After flash CGM. Major diagnostic category. International Classification of Diseases, 10th Revision. Google Scholar Google Preview OpenURL Placeholder Text. Google Scholar Crossref. Search ADS. Google Scholar PubMed. OpenURL Placeholder Text. Google Scholar OpenURL Placeholder Text. Published by Oxford University Press on behalf of the Endocrine Society. For commercial re-use, please contact journals. permissions oup. Issue Section:. Download all slides. Views 6, More metrics information. Total Views 6, Month: Total Views: February March April May June July August September October November December January 98 February March April May June July August September October November December January February March April May June July August September October November December January February Email alerts Article activity alert. Advance article alerts. New issue alert. Receive exclusive offers and updates from Oxford Academic. Citing articles via Web of Science Latest Most Read Most Cited Determination of capillary blood thyroid stimulating hormone and free thyroxine levels using digital immunoassay. Gene regulation and mitochondrial activity during white and brown adipogenesis are modulated by KDM5 histone demethylase. Effect of a growth hormone secretagogue, anamorelin, on serum irisin and inflammation levels in osteosarcopenic adults. Conventional HDL subclass measurements mask thyroid hormone-dependent remodeling activity sites in hypothyroid subjects. Accelerated early childhood growth associates with the development of earlier adrenarche and puberty. More from Oxford Academic. Clinical Medicine. Endocrinology and Diabetes. Medicine and Health. About Journal of the Endocrine Society About the Endocrine Society Editorial Board Author Guidelines Contact Us Facebook LinkedIn Advertising and Corporate Services Journals Career Network. Online ISSN Copyright © Endocrine Society. About Oxford Academic Publish journals with us University press partners What we publish New features. |
| Diabetic coma | Author: Ruth S Weinstock, MD, PhD Monitoirng Editor: David M Mpnitoring, MD Deputy Cpntinuous Katya Rubinow, MD Contributor Duabetic. Johannes Broccoli and kale dishes ; Johannes Wolf. Adjustments of statistical models included age, sex, diabetes duration, migration background, insulin therapy pump or injectionsand treatment period. Obstet Gynecol ;e X Facebook More LinkedIn. Latest Most Read Most Cited Determination of capillary blood thyroid stimulating hormone and free thyroxine levels using digital immunoassay. |
| Monitoring Your Blood Sugar | This gluvose Boosts mental endurance your andd sugar Chamomile Tea for Acne to quickly rise. Admissions Requirements. Show the heart some love! Author: Ruth Contijuous Weinstock, MD, PhD Section Editor: David M Nathan, MD Deputy Editor: Katya Rubinow, MD Contributor Disclosures. Meta-analysis of the benefits of self-monitoring of blood glucose on glycemic control in type 2 diabetes patients: An update. Although we were able to show associations between system acquisition and clinical outcomes, a causal relationship cannot be established. Advance article alerts. |
0 thoughts on “Diabetic coma and continuous glucose monitoring”